Australia's most trusted
source of pharma news
Wednesday, 26 March 2025
Posted 24 March 2025 AM
The TGA has approved two innovative orphan medicines – Astellas Pharma's pegged blockbuster Vyloy and Ballia Holding’s Joenja.
Vyloy in combination with fluoropyrimidine and platinum-containing chemotherapy, is indicated for the first line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastro-oesophageal junction adenocarcinoma whose tumours are Claudin 18.2 positive.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.